Oryzon Genomics attracts the interest of investors again, after the publication of the results of the studies on different mental illnesses. The actions of the Biopharmaceutical Company, which has among its strategic objectives jump to Nasdaq, have come to rise on Monday around 21%, up to 3.69 euros, the greatest advance in three years, and prolong the rally starring the last week. After noon, the rise is around 17%. Since the beginning of the year, carrying the stock market capitalization above the level of 230 million euros. The average target price of the action granted by the analysts who follow the company is 5.77 euros.
At the beginning of last week, Oryzon announced the final results of the IIA Reimagine Phase study, which evaluated Vafidemstat’s safety and effective (ADHD) and Autistic Spectrum Disorder (TEA). These results were published in the magazine.
According to the company, the publication of these results in this prestigious clinical psychiatry magazine is part of Oryzon’s continued effort to expand current knowledge about the relevance of epigenetics in psychiatry and neurodevelopmental disorders. “This innovative study, one of the first CASETA in CNC, was the first to demonstrate that treatment with LSD1 inhibitors is a mechanism of safe and totally novel action to treat agitation/aggression in psychiatric diseases,” said the company
His CEO, Carlos Buesa, said that Vafidemstat is a promising molecule to control agitation and aggressiveness in various SNC disorders, as demonstrated in this phase IIA trial. “We are excited to design a phase III essay on FTA, with the advice of prominent American psychiatrists, to evaluate its impact on this highly disabled characteristic of the disease. Agitely mitigating agitation and aggression could significantly improve the daily life of patients with FTA. If the next phase III trial yields positive results, Vafidemstat could be explored more broadly in the control of aggression in other CNS disorders. ”
Advances in these treatments are key to the company. Last October, he received the official act of his final-of-phase II meeting for Vafidemstat in personality limit disorder (TLP) with the US Food and Drug Administration (FDA or agency responsible for verifying medicines) of the United States. The company then said that, after the positive comments received, it was going to initiate the preparation of a complete protocol for phase III Portico-2 study that would subsequently be presented to the FDA for approval.
In 2024, the Oryzon Shareholders Board authorized the Board of Directors to carry out a capital increase, through monetary contributions and excluding the preferential subscription right, in an effective amount of up to 100 million euros. .
Changes in the Council
The company has also started the year with changes of relevance in its directive dome and board of directors. Oryzon has appointed Pierre Beaurang as a new business strategy and development advisor. The Executive has been CEO and a member of the Council of Nitrase Therapeutics, a private biotechnology company focused on a new class of enzymes involved in neurodegenerative disorders and cancer, and, previously, Nurix Therapeutics business director.
The pharmacist also reported that it will propose the incorporation of four new members to the Council: the aforementioned Pierre Beaurang, Konstantinos Allataris, Montse Vendrell and Luis Sánchez Quintana. In reverse, they will leave their advice Ramón Adell, Isabel Aguilera, Antonio Fornieles, Josep María Echarri, a strong man of Inveready, and Tamara Maestro.
